Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 15;2009(2):CD006316.
doi: 10.1002/14651858.CD006316.pub3.

Pneumococcal vaccines for children and adults with bronchiectasis

Christina C Chang  1 , Rosalyn J Singleton, Peter S Morris, Anne B Chang
Affiliations

Pneumococcal vaccines for children and adults with bronchiectasis

Christina C Chang et al. Cochrane Database Syst Rev. .

Abstract

Background: Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries. Even in affluent countries, bronchiectasis is increasingly seen in some community subsections (e.g. Aboriginal communities) and occurs as a comorbidity and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease (COPD). Respiratory exacerbations in people with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Conjugate pneumococcal vaccine is part of the routine infant immunisation schedule in many countries. Current recommendations for additional pneumococcal vaccination include children and adults with chronic suppurative disease.

Objectives: To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline.

Search strategy: The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of pneumococcal vaccines were also contacted. The latest searches were performed in November 2008.

Selection criteria: All randomised controlled trials that utilised pneumococcal vaccine on children and adults with bronchiectasis. All types of pneumococcal vaccines were included.

Data collection and analysis: Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data was available for analysis. One small non-randomised controlled trial in children was reported.

Main results: One randomised controlled open label study in 167 adults with chronic lung disease (bronchiectasis and other diseases associated with bronchiectasis) compared 23-valent pneumococcal (PV) and influenza vaccine with influenza vaccine alone (control group). The study found a significant reduction in acute infective respiratory exacerbations in the PV group compared to the control group, OR=0.48 (95%CI 0.26, 0.88); number needed to treat to benefit = 6 (95%CI 4, 32) over 2-years. There was however no difference in episodes of pneumonia between groups and no data on pulmonary decline was available. In another study, a benefit in elimination of Strep. pneumoniae in the sputum was found in a non-randomised trial in children but no clinical effect was described.

Authors' conclusions: Current but limited evidence support the use of 23-valent pneumococcal vaccine as routine management in adults with bronchiectasis. Circumstantial evidence also support the use of routine 23-valent pneumococcal vaccination in children with bronchiectasis. Further randomised controlled trials examining the efficacy of this intervention using various vaccine types in different age groups are needed. There is no data on the efficacy of pneumococcal vaccine on pulmonary decline. With the lack of evidence in how often the vaccine should be given, it is recommended that health providers adhere to national guidelines.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

1
1
Forest plot of comparison: 1 Adults, outcome: 1.2 Number of people with acute respiratory exacerbation.
2
2
Cates plot for NNT (B) over 2‐years in reduction of infective exacerbation comparing PV23 vaccination to control in adults with chronic lung disease
1.1
1.1. Analysis
Comparison 1 Adults, Outcome 1 Number of people with one or more acute respiratory exacerbation.
1.2
1.2. Analysis
Comparison 1 Adults, Outcome 2 Number of subjects with pneumonia.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Furumoto 2008 {published data only}
    1. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008;26(33):4284‐9. - PubMed

References to studies excluded from this review

Ryzhov 2005 {published data only}
    1. Ryzhov AA, Katosova LK, Kostinov MP, Volkov IK, Magarshak OO. Evaluation of the influence of the bacterial vaccines Pneumo‐23 and Act‐HIB on the course of the chronic inflammatory process of the respiratory organs in children. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 2005;30(3):84‐7. - PubMed
van Kessel 2005 {published data only}
    1. Kessel DA, Velzen‐Blad H, Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. European Respiratory Journal 2005;25(3):482‐9. - PubMed
Vendrell 2005 {published data only}
    1. Vendrell M, Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005;127(1):197‐204. - PubMed

References to studies awaiting assessment

O Grady 2015 {published data only}
    1. O'Grady KA, Grimwood K, Cripps A, Mulholland EK, Morris P, Torzillo PJ, et al. Does a 10‐valent pneumococcal‐Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials 2013;14(1):282. - PMC - PubMed

Additional references

ACIP
    1. ACIP. Advisory Committee on Immunization Practices. http://www.cdc.gov/nip/menus/vaccines.htm (accessed Dec 2006).
Altin 2004
    1. Altin R, Savranlar A, Kart L, Mahmutyazicioglu K, Ozdemir H, Akdag B, et al. Presence and HRCT quantification of bronchiectasis in coal workers. European Journal of Radiology 2004;52(2):157‐63. - PubMed
Buckles 1951
    1. Buckles MG, Potts WL, Davidson HB, Neptune WB. Bronchography in pulmonary tuberculosis, with histopathologic correlation in 82 resections. American Review of Tuberculosis 1951;64(4):394‐407. - PubMed
Callahan 2002
    1. Callahan CW, Redding GJ. Bronchiectasis in children: orphan disease or persistent problem?. Pediatric pulmonology 2002;33(6):492‐496. - PubMed
Cates 2003
    1. Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 4. [Art. No.: CD000364. DOI: 10.1002/14651858.CD000364.pub2.] - PubMed
Chang 1998
    1. Chang AB, Masel JP, Masters B. Post‐infectious bronchiolitis obliterans: clinical, radiological and pulmonary function sequelae. Pediatric Radiology 1998;28(1):23‐29. - PubMed
Chang 2002
    1. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. Medical Journal of Australia 2002;177(4):200‐4. - PubMed
Chang 2003
    1. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non‐CF bronchiectasis‐clinical and HRCT evaluation. Pediatric Pulmonology 2003;35:477‐83. - PubMed
Cole 1986
    1. Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. European Journal Respiratory Disease 1986;147(Suppl):6‐15. - PubMed
Conaty 2004
    1. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004;22(23‐24):3214‐24. - PubMed
de Roux 2005
    1. Roux A, Lode H. Pneumococcal vaccination. European Respiratory Journal 2005;26(6):982‐3. - PubMed
Devitt 1977
    1. Devitt L, Riley I, Hansman D. Human infection caused by penicillin‐insensitive pneumococci. Medical Journal of Australia 1977;1(16):586‐8. - PubMed
Forrester 1987
    1. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high‐risk population. American Journal of Medicine 1987;83(3):425‐30. - PubMed
Granger 2006
    1. Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.: CD001390. DOI: 10.1002/14651858.CD001390.pub2.] - PubMed
Gursel 2006
    1. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?. Heart Lung 2006;35(1):58‐65. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2008.
Honkanen 1999
    1. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17(20‐21):2493‐500. - PubMed
Jackson 2006
    1. Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006;24(2):151‐6. - PubMed
Jefferson 2006
    1. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006;333(7574):912‐5. - PMC - PubMed
Karadag 2005
    1. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non‐cystic‐fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005;72(3):233‐8. - PubMed
Keistinen 1997
    1. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly‐understood prognosis. European Respiratory Journal 1997;10(12):2784‐7. - PubMed
Lee 2003
    1. Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Critical Reviews in Microbiology 2003;29(4):333‐49. - PubMed
Lewis 2002
    1. Lewis MM, Mortelliti MP, Yeager H, Jr, Tsou E. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis, vasculitis, and diffuse lung diseases 2002;19(2):154‐9. - PubMed
Lexau 2005
    1. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043‐51. - PubMed
Lucero 2004
    1. Lucero MG, Dulalia VE, Parreno RN, Lim‐Quianzon DM, Nohynek H, Makela H, et al. Pneumococcal conjugate vaccines for preventing vaccine‐type invasive pneumococcal disease and pneumonia with consolidation on x‐ray in children under two years of age (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 4. [Art. No.: CD004977. DOI: 10.1002/14651858.CD004977.] - PubMed
Martinez‐Garcia 2005
    1. Martinez‐Garcia MA, Perpina‐Tordera M, Roman‐Sanchez P, Soler‐Cataluna JJ. Quality‐of‐life determinants in patients with clinically stable bronchiectasis. Chest 2005;128(2):739‐45. - PubMed
McEllistrem 2005
    1. McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, et al. Acute otitis media due to penicillin‐nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clinical Infectious Diseases 2005;40(12):1738‐44. - PubMed
NIPS
    1. National Immunisation Program. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Conte... accessed Dec 2006.
O'Brien 2000
    1. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635‐42. - PMC - PubMed
Patel 2004
    1. Patel IS, Vlahos I, Wilkinson TM, Lloyd‐Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2004;170(4):400‐7. - PubMed
Poletti 2006
    1. Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. European Respiratory Journal 2006;28(4):862‐71. - PubMed
Sheikh 2002
    1. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD002165] - DOI - PubMed
Singleton 2000
    1. Singleton RJ, Morris A, Redding G, Poll J, Holck P, Martinez P, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182‐7. - PubMed
Straetemans 2004
    1. Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Pneumococcal vaccines for preventing otitis media (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD001480.pub2] - DOI - PubMed
Twiss 2006
    1. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414‐8. - PMC - PubMed
Walker 2005
    1. Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clinical Infectious Diseases 2005;40(12):1730‐5. - PubMed

Publication types

MeSH terms

Substances